GO
Loading...

Enter multiple symbols separated by commas

Stocks Sanofi SA

More

  • Linking cancer drug prices to their performance Wednesday, 27 May 2015 | 1:54 PM ET

    Express Scripts is looking at the possibility of paying more for drugs that have been proven to show more benefit, and less where the drug hasn't.

  • Assuming approval from the U.S. Food and Drug Administration, Amgen Inc. will offer its drug, Repatha, as a biweekly 140 mg injection or a monthly injection of 420 mg, while Praluent, from Regeneron Pharmaceuticals Inc and Sanofi, will be offered in biweekly injections of 75 mg or 150 mg. Regeneron and Sanofi could enjoy a significant pricing advantage with their...

  • CHICAGO/ NEW YORK, May 22- As a virulent avian influenza outbreak continues to spread across the Midwestern United States, some egg-dependent companies are contemplating drastic steps- importing eggs from overseas or looking to egg alternatives. A spokeswoman for Archer Daniels Midland Co said that as egg supplies tighten and prices rise, the food processing...

  • CHICAGO and NEW YORK, May 22- As a virulent avian influenza outbreak continues to spread across the Midwestern United States, some egg-dependent companies are contemplating drastic steps: importing eggs from overseas or looking to egg alternatives. "Canada is short on eggs and has been buying heavily from the U.S. for the last several years," said Rick Brown, a...

  • LONDON, May 19- Amgen's new cholesterol drug Repatha could be recommended for approval in Europe as early as this week, putting it ahead in a race with a rival product from Sanofi. Recommendations for marketing approval by its Committee for Medicinal Products for Human Use are normally endorsed by the European Commission within a couple of months.

  • Regeneron Pharmaceuticals Inc, which signed a deal with Pennsylvania's Geisinger Health System in January 2014 to sequence partial genomes of some 250,000 volunteers, is already claiming discoveries based on the new approach. Pfizer Inc, Roche Holding AG and Biogen Inc are working on similar projects that use DNA and patient health data to find new drug...

  • These biotech names are ripe for mergers: Analysts Sunday, 10 May 2015 | 11:00 AM ET
    Biotech pharmaceuticals

    The next takeout target in biotech? Here are three eligible candidates

  • Hedgie: This biotech stock is going to zero Thursday, 7 May 2015 | 12:49 PM ET
    Afrezza is a rapid-acting, inhaled insulin for the treatment of diabetes.

    The hedge fund manager who has already made a killing betting against biotech company MannKind now says the stock will soon be worthless.

  • May 7- Regeneron Pharmaceuticals Inc said it expects sales of blockbuster eye injection Eylea to grow at a faster rate than it had previously forecast. Sales of Eylea in the United States jumped 51 percent to $541 million in the first quarter ended March 31, helping the company's adjusted profit handily beat the average analyst estimate by 20 cents.

  • Regeneron profit rises as Eylea sales jump Thursday, 7 May 2015 | 6:39 AM ET

    May 5- Regeneron Pharmaceuticals Inc reported an 11 percent rise in quarterly profit, driven by surging demand for its top-selling eye drug, Eylea. The U.S. biotechnology company's net profit rose to $76 million, or 66 per share, in the first quarter ended March 31, from $68.3 million, or 61 cents per share, a year earlier. Revenue, including collaboration payments...

  • WASHINGTON, May 6- The U.S. Food and Drug Administration will hold a public meeting this summer to address drug company concern that restrictions on what they can say about off-label use of drugs violate their first amendment right to free speech. Efforts by drug companies to change the rules gained steam after a 2012 decision from the Second Circuit Court of...

  • *Sacked former CEO's 4.44 million euros exit deal approved. *Brandicourt also gets extra 4 million euros golden hello. Investor advisory group ISS had recommended a vote against both resolutions, prompting the Sanofi board to appeal for loyalty and call ISS's advice "a real error in analysis."

  • *Sanofi says opposition to both deals a "real error". PARIS, April 30- Drugs group Sanofi, which sacked its chief executive last year and appointed a new one in February, has appealed for shareholder loyalty as it seeks to head off a potential rebellion over millions of euros in payments to both men. In exchange, he agreed not to work for a competitor until June, not to...

  • Biotech's boom fuels real estate here Thursday, 30 Apr 2015 | 12:11 PM ET
    Signage sits on display in an atrium at Genzyme Corp.'s headquarters in Cambridge, Massachusetts.

    As biotech has boomed over the last few years, so has real estate in Kendall Square in Cambridge, Massachusetts.

  • Market digs for next clue for data dependent Fed Thursday, 30 Apr 2015 | 6:03 AM ET
    The Marriner S. Eccles Federal Reserve Building in Washington.

    The markets quickly shifted focus from the Fed meeting to the upcoming April jobs report.

  • PARIS, April 30- France's Sanofi warned revenue in its key diabetes division would fall this year after it was forced to offer discounts for its best-selling drug Lantus in the United States. Global sales of Lantus, which accounts for almost a fifth of the company's revenue but is due to go off-patent in the United States this year, fell 5 percent at constant...

  • Sanofi keeps 2015 guidance with steady Q1 profits Thursday, 30 Apr 2015 | 1:42 AM ET

    PARIS, April 30- Drugs firm Sanofi maintained its guidance for stable to slightly growing 2015 profit on Thursday as first-quarter earnings grew modestly and beat expectations despite declining sales of its main drug Lantus. But this impact was offset by strong operating profit growth in its Genzyme, Generics, Consumer Healthcare and Animal Health...

  • What you need to know for Thursday trading Wednesday, 29 Apr 2015 | 5:33 PM ET
    The Marriner S. Eccles Federal Reserve Building in Washington.

    The markets quickly shifted focus from the Fed meeting to the upcoming April jobs report.

  • *Celladon trial failure shows field remains high-risk. LONDON, April 27- GlaxoSmithKline is close to seeking European approval for a gene therapy drug to fight the immune deficiency disorder known as "bubble boy" disease, in the latest sign of a renaissance in the technology to fix faulty genes. Gene therapy last year won $3.0 billion of financing, up 510 percent on...

  • Why the S&P could break out this week Monday, 27 Apr 2015 | 7:12 AM ET
    Traders work on the floor of the New York Stock Exchange.

    As the Fed meets and earnings news rains down, the big question in the week ahead is whether the S&P 500 can manage a break out.